Biopharmaceutical company Immuron Ltd (ASX:IMC) has successfully reached the 50% recruitment milestone for the company’s phase II clinical trial for the treatment of Non-Alcoholic Steatohepatitis (fatty liver disease).
Immuron now has a total of 28 active clinical study sites across the USA, Australia and Israel with 56 patients having been randomised.
Significantly the 25 patients successfully completed treatment with its proprietary compound IMM-124E with no significant adverse effects or safety issues reported.
Immuron is expected to complete the recruitment during the second half of 2016.
The company currently markets and sells Travelan tablets for the prevention of Travellers’ diarrhoea and Protectyn, a natural dietary supplement.
Immuron is aggressively marketing the products, signing up with QBID of China earlier this month to tap into the multi-million dollar Chinese market.
QBID is an official partner of JD.com, China's largest online direct sales company, for products sourced from Australia and New Zealand.
In addition to the Chinese deal, Immuron had executed a North American distribution agreement last month with McKesson Corporation (NYSE:MCK), the largest healthcare distribution company in the world with US$179 billion revenue in 2015.
The company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea which is now distributed through CVS Pharmacies - one of the largest retailers in the U.S.
Immuron had a cash balance of $994,151 as on 31 December, 2015.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.